Amgen Inc. (AMGN) Price and Market Data

Amgen Inc. is a leading biotechnology company focused on human therapeutics. Its flagship products include red blood cell stimulators Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and the inflammatory disease treatments Enbrel and Otezla. Amgen launched its first cancer therapy, Vectibix, in 2006 and also markets bone-health drugs Prolia/Xgeva, approved in 2010, and Evenity, introduced in 2019. The acquisition of Onyx Pharmaceuticals strengthened Amgen’s oncology portfolio with Kyprolis. More recent product launches include Repatha for cholesterol management, Aimovig for migraine prevention, Lumakras for lung cancer, and Tezspire for asthma. In 2023, the Horizon acquisition added several rare disease medicines, including thyroid eye disease treatment Tepezza. Amgen also continues to expand its biosimilar portfolio.